MedTrace Logo

Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

NCT00388687 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2006-10-17

No results posted yet for this study

Summary

The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA.

Conditions

  • Uterine Cervical Neoplasms

Interventions

DRUG

18F Fluoroazomycin Arabinoside (FAZA)

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Georgios Karanikas, Prof. M.D. · Medical Universitiy of Vienna

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Completion
2007-07-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388687 on ClinicalTrials.gov